孕激素治疗晚期和复发性子宫内膜癌的效果:系统综述与Meta分析
该系统综述与Meta分析纳入26项研究共1639例晚期或复发性子宫内膜癌患者,评估孕激素单药治疗的缓解率与毒性。总缓解率为30%(95%CI 25-36),临床获益率为52%(95%CI 42-61);孕激素受体阳性者总缓解率55%,阴性者12%(风险差43%,95%CI 15-71);严重毒性发生率为6.5%。
要点
- 孕激素治疗晚期或复发性子宫内膜癌的总缓解率为30%(95%CI 25-36),临床获益率为52%(95%CI 42-61)。
- 孕激素受体阳性者总缓解率为55%,阴性者为12%,风险差43%(95%CI 15-71)。
- 严重毒性发生率为6.5%。
核心结论
- 孕激素治疗是晚期和复发性子宫内膜癌患者可行的治疗选择,毒性低,且在孕激素受体阳性疾病中总缓解率高。
- 孕激素受体表达与无进展生存期和总生存期的关系尚不明确。
研究设计与样本
- 系统综述与Meta分析,检索Pubmed、Embase和Cochrane数据库,纳入26项研究共1639例患者。
- 纳入标准为晚期或复发性子宫内膜癌患者接受孕激素单药治疗的研究;排除辅助治疗、病例数少于10例及肉瘤组织学的研究。
- 采用修订版Cochrane RoB2工具评估随机研究偏倚,采用ROBINS-I工具评估非随机研究偏倚;以总缓解率、临床获益率和毒性为主要结局指标进行随机效应Meta分析。
主要发现
- 孕激素治疗的总缓解率为30%(95%CI 25-36),临床获益率为52%(95%CI 42-61)。
- 孕激素受体阳性子宫内膜癌的总缓解率为55%,孕激素受体阴性者为12%(风险差43%,95%CI 15-71)。
- 严重毒性发生率为6.5%。
关键数值与推荐
- 总缓解率30%(95%CI 25-36),临床获益率52%(95%CI 42-61)。
- 孕激素受体阳性者总缓解率55%,孕激素受体阴性者12%,风险差43%(95%CI 15-71)。
- 严重毒性发生率6.5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fifteen percent of patients with endometrial cancer (EC) have advanced stage disease or develop a recurrence. Progestins have been applied as systemic treatment for decades, but there is limited evidence on response prediction with biomarkers and toxicity. OBJECTIVES: To review the response and toxicity of progestin therapy and stratify response to progesterone receptor (PR) expression and tumour grade. SEARCH STRATEGY: We used the search terms 'Endometrial cancer', 'Progestins', 'Disease progression', 'Recurrence' and related terms in Pubmed, Embase and Cochrane databases. SELECTION CRITERIA: Studies on patients with advanced stage or recurrent EC treated with progestin monotherapy were included. Studies on adjuvant therapy, with fewer than ten cases and with sarcoma histology were excluded. DATA COLLECTION AND ANALYSIS: Evaluation for bias was performed with the Revised Cochrane RoB2 tool for randomised studies and the ROBINS-I tool for non-randomised studies. A random effects meta-analysis was performed with the overall response rate (ORR), clinical benefit rate and toxicity as primary outcome measures. MAIN RESULTS: Twenty-six studies (1639 patients) were included. The ORR of progestin therapy was 30% (95% CI 25-36), the clinical benefit rate was 52% (95% CI 42-61). In PR-positive EC, the ORR was 55%, compared with 12% in PR-negative disease (risk difference 43%, 95% CI 15-71). Severe toxicity occurred in 6.5%. CONCLUSIONS: Progestin therapy is a viable treatment option in patients with advanced stage and recurrent EC with low toxicity and high ORR in PR-positive disease. The role of PR expression in relation to progression-free survival and overall survival is unclear.
引用
- van Weelden WJ, Birkendahl PB, Lalisang RI, et al. The effect of progestin therapy in advanced and recurrent endometrial cancer: A systematic review and meta-analysis. BJOG. 2022. PMID: 36264251. doi:10.1111/1471-0528.17331
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。